for the Veterans Aging Cohort Study Background-Whether hepatitis C virus (HCV) confers additional coronary heart disease (CHD) risk among human immunodeficiency virus (HIV) infected individuals is unclear. Without appropriate adjustment for antiretroviral therapy, CD4 count, and HIV-1 RNA and substantially different mortality rates among those with and without HIV and HCV infection, the association between HIV, HCV, and CHD may be obscured. Methods and Results-We analyzed data on 8579 participants (28% HIVϩ, 9% HIVϩHCVϩ) from the Veterans Aging Cohort Study Virtual Cohort who participated in the 1999 Large Health Study of Veteran Enrollees. We analyzed data collected on HIV and HCV status, risk factors for and the incidence of CHD, and mortality from January 2000 to July 2007
HIVϪHCVϪ patients, 1, 8 we constructed competing risk models to ensure that the association between HIV, HCV, and incident CHD was not obscured by an excess (competing) risk of death.
WHAT IS KNOWN
• Whether hepatitis C virus (HCV) infection confers additional coronary heart disease risk over and above that of human immunodeficiency virus (HIV) infection is not clear. • The prior studies involving HIV and coronary heart disease do not compare HIV-infected people with HIV-uninfected people who are demographically and behaviorally similar.
WHAT THE STUDY ADDS
• HIV and HCV coinfection is associated with a higher risk of coronary heart disease as compared with HIV monoinfection and compared with no HIV and no HCV infection. • The HIV-infected and HIV-uninfected people in this study were demographically and behaviorally similar. • The association between HIV and HCV coinfection and coronary heart disease persisted even after adjusting for the high mortality rate among HIV and HCV coinfected people, using competing risk models.
Methods
The Virtual Cohort is a cohort of HIV-infected, age, sex, race/ ethnicity, and clinical site-matched HIV-uninfected participants identified from United States Department of Veterans Affairs (VA) administrative data in the fiscal years 1998 to 2003, using a modified existing algorithm. 6 This cohort consists of data from the immunology case registry; the VA HIV registry; the pharmacy benefits management data base, a VA centralized data base of outpatient prescriptions; the decision support system, a national data base of VA clinical and financial data including laboratory data; and the National Patient Care Database. The 1999 Large Health Study of Veteran Enrollees, a survey administered between June 1999 and January 2000, was designed to assess the health status of Veterans in the Veterans Health Administration. It contained the Veterans RAND 36 Item Health Survey (VR-36) instrument and other measures of sociodemographic and economic status. 7, 9 The institutional review boards at the University of Pittsburgh, Yale University, and the West Haven Veterans Administration Medial Center approved this study. All participants in the Virtual Cohort/Large Health Study data set (nϭ13 250) were eligible for the present study. After excluding participants with baseline cardiovascular disease and cancer, participants who failed to answer baseline questions about cancer, and women (because of small numbers), our final sample included 8579 participants.
Independent Variable
We categorized participants into 1 of 4 groups: HIVϩHCVϩ, HIVϩHCVϪ, HIVϪHCVϩ, and HIVϪHCVϪ uninfected (referent). HIV infection was defined as a participant with Ն1 inpatient and/or Ն2 outpatient International Classification of Diseases (ICD)-9 codes for HIV infection and confirmed by the participant's presence in the immunology case registry. 6 HCV infection was defined as a positive HCV antibody test or Ն1 inpatient and/or Ն2 outpatient ICD-9 codes for this diagnosis. 10
Dependent Variable(s)
We used ICD-9 codes (410 -411) to identify incident acute myocardial infarction and unstable angina events (CHD) events from January 2000 (entry into the Large Health Study) to July 2007. We chose these ICD-9 codes on the basis of the positive predictive value of the diagnosis of acute myocardial infarction in the Veterans Health Administration 11 and the high agreement between these ICD-9 codes (both inpatient and outpatient ICD-9 codes) and formal reviewer adjudication in the Cardiovascular Health Study. 12 Follow-up time was to a CHD or death event or the last known visit within the VA system. In contrast to a prior study that used only inpatient VA hospitalization data to assess the risk of cardiovascular disease among HIV-infected Veterans, 13 the present study incorporates both inpatient and outpatient ICD-9 codes. Outpatient ICD-9 codes were used to capture participants who had non-VAhospitalized CHD events but subsequently received their follow-up CHD care as part of the VA outpatient clinical care system. In the Veterans Aging Cohort Study, all CHD events are being formally adjudicated, using established protocols as part of a National Heart, Lung, and Blood Institute-funded collaborative research initiative. This process is not yet complete. We have observed after reviewing charts of nearly 4000 participants that approximately 90% of the acute myocardial infarctions occurring within and outside the VA hospital system were captured by using inpatient and outpatient ICD-9 codes 410 and 411. We confirmed deaths by using the VA vitals status file; the Social Security Administration death master file, the Beneficiary Identification and Records Locator Subsystem, and the VHA medical SAS inpatient data sets.
Covariates
Sociodemographic data included age, race/ethnicity, and level of education. Hypertension was defined with the use of ICD-9 codes. Diabetes was diagnosed by using a combination of glucose measurements, diabetic medication use, and or ICD-9 codes. We calculated body mass index (kg/m 2 ) by using self-reported height and weight.
Smoking was categorized as history of current smoking, past smoking, or never smoking. Hypercholesterolemia was defined as use of a HMG-CoA reductase inhibitor medication; a total cholesterol value Ͼ200 mg/dL; or ICD-9 codes. History of cocaine dependence and abuse was defined by means of ICD-9 codes (304.20 to 304.23 and 305.6 to 305.63). History of alcohol dependence and abuse were defined by means of ICD-9 codes, based on prior work in the VACS. 14 Among the HIV-infected Veterans, we collected data on baseline and recent CD4 cell counts and HIV-1 RNA. Baseline CD4 count and HIV-1 RNA measurements were from 180 days before and up to 180 days after the time of enrollment in the Large Health Study, and recent measurements were the CD4 count and HIV-1 RNA collected closest to the date of the incident CHD event, mortality event, or the date of last follow-up observation. Duration of antiretroviral therapy (ART) was calculated by using the number of days a participant was taking ART. Duration of ART, calculated on the basis of prescription refill data in the pharmacy benefits management data base, was available from the time of enrollment into the Large Health Study through June 2005. We calculated the duration of ART by drug classes: protease inhibitors (PI), nonnucleoside reverse transcriptase inhibitors (NNRTI), and nucleoside reverse transcriptase inhibitors (NRTI). We also analyzed recent ART because recent studies suggest that ART taken within 6 months of a CHD event is significantly associated with an increased risk of CHD. 15, 16 Recent ART was defined as the use of ART by drug classes within 180 days of an incident CHD or mortality event or the date of last ART prescription recorded among those who did not have a CHD or mortality event. All ART medications that were available on the VA formulary during the time period of this study were considered in the analyses.
Statistical Methods
Descriptive statistics for all variables by HIV and HCV status were assessed with the use of t tests or its nonparametric counterpart for continuous variables and 2 test or Fisher exact test for categorical variables. When treating death as a censoring event, Cox proportional hazard models were used to estimate the hazard ratio (HR) and 95% confidence intervals (CI) for incident CHD associated with HIV and HCV status after adjusting for confounders. The proportional hazards assumption was assessed with the use of the Grambsch-Therneau method. 17 We calculated age and race/ethnicity-adjusted incident CHD per 1000 person-years and mortality rates per 100 person-years. Multiple imputation was used to generate 5 data sets with complete covariate values to increase the robustness and efficiency of the estimated hazard ratio.
This sample represents HIV participants at the earliest period of combination ART. The mortality rates among those infected with HIV were substantially higher compared with Veterans not infected with HIV. Similarly, mortality rates among HIVϩHCVϩ were higher than those among HIVϪHCVϩ. Cox proportional hazard models assume "noninformative censoring"; this means that patients censored (because of death or loss to follow-up) do not depend on the prognosis of developing CHD. This assumption is violated if HIVϩHCVϩ Veterans have both substantially higher mortality rates and are at greater risk of CHD than HIVϩHCVϪ and HIVϪHCVϪ Veterans. Therefore, we conducted secondary analyses to ensure that the high mortality rates were not obscuring the association between the HIV and HCV status and incident CHD. To do this, we constructed regression models that incorporated death as a competing risk. Fine and Gray methodology requires that participants who have the competing event (ie, death) would never have died of CHD or developed the event of interest (ie, CHD) if they had not died of a non-CHD death and completed the follow-up period. 18 This seems an implausible assumption for our analyses. Thus, to adapt this technique to account for differing underlying risks of CHD, we needed to identify among those participants who died, probability of either dying of CHD, or having CHD in the follow-up period. We calculated propensity scores by means of a multivariable logistic regression model to assess the likelihood of development of CHD, given an observed set of CHD risk factors (age, race, body mass index, hypertension, diabetes, current smoking, hypercholesterolemia, and cocaine use). 19 The model's calculated c-statistic (0.75, which represents good prediction of the likelihood of development of CHD), was used to assess the predictive capacity of the model. 20 We then used the propensity score to identify, among those who died, who was at a high risk of dying of CHD or having CHD in the follow-up period. Each person was then reclassified into 1 of 3 categories: died of CHD; did not die of CHD but would have had CHD in the follow-up period; or did not die of CHD and did not have CHD in the follow-up period. Once participants were reclassified; we could then apply the Fine and Gray technique to our sample. It is important to note that during the median follow-up period of 7.3 years, 48 of the 254 HIVϩHCVϩ Veterans who died had propensity score estimates consistent with death from CHD or development of CHD during the follow-up period if they have not died of another cause.
For analyses restricted to HIV-infected participants, we added HIV-1 RNA, CD4 count, ART status, and traditional risk factors into the model. Our analyses considered baseline, duration of and recent ART, as well as baseline and recent CD4 count and HIV-1 RNA. Because ART data were only available through June 2005, these analyses were truncated to 2005.
Results
We excluded participants who reported at baseline CHD, congestive heart failure and stroke (nϭ3116), or cancer (except nonmelanomatous skin cancer, nϭ856) or who failed to answer questions regarding prevalent cancer (nϭ860). Women were excluded because of limited numbers (nϭ276). After these exclusions, our final sample size was 8579 participants (28% HIV-infected). Among the study participants, the prevalence of all established cardiovascular risk factors differed by HIV and HCV status (PՅ0.001 for all Table 1 ). Compared with HIVϩHCVϩ Veterans, the number of days on NNRTI and NRTI use and the prevalence of recent use of NRTI use was higher among HIVϩHCVϪ Veterans (PϽ0.05 for all, Table 1 Compared with HIVϪHCVϪ Veterans, HIVϩHCVϩ Veterans had significantly higher risks of incident CHD (Figure 2) , whether death was censored or treated as a competing risk ( Table 2) . We examined the association between HIVϩHCVϩ and incident CHD by using models that adjust for death as a competing risk (Table 2) because CHD and mortality rates were highest among coinfected Veterans.
Compared with HIVϩHCVϪ Veterans, HIVϩHCVϩ Veterans had a higher risk of incident CHD, regardless of whether death was censored or treated as a competing risk (Table 3) . This association persisted even after adjusting for traditional risk factors; baseline, duration of, and recent antiretroviral therapy (Table 3 ; models 1, 2, and 3, respectively); and baseline and recent HIV viral load and CD4 count (Table 3, model 3). Recent PI use (HR, 2.15; 95% CI, 0.99 to 4.65), recent NNRTI use (HR, 1.40; 95% CI, 0.70 to 2.77), and recent HIV-1 RNA Ͼ500 (HR, 1.29; 95% CI, 0.68 to 2.45) were not significantly associated with an increase in CHD. At baseline, classes of ART and duration of PI and NNRTI were also not significantly associated with CHD in multivariable models. Duration of NRTI per year was associated with a reduced risk of CHD (HR, 0.69; 95% CI, 0.53 to 0.90). The association between ART and mortality by class of ART was HR, 0.97; 95% CI, 0.88 to 1.07 for PI; HR, 0.97; 95% CI, 0.88 to 1.07 for NNRTI; and HR, 0.69; 95% CI, 0.63 to 0.76 for NRTI, respectively.
Discussion
Our findings suggest that HIVϩHCVϩ Veterans have an increased risk of CHD after adjustment for traditional CHD risk factors, use of ART; CD4 count, and HIV-1 RNA compared with HIVϩHCVϪ, and HIVϪHCVϪ Veterans. This association persisted whether death was treated as a censored event or a competing risk. Currently there are no prospective data describing the risk of incident CHD among HIVϩHCVϩ individuals compared with HIVϪHCVϪ individuals who are similar demographically and behaviorally. The data describing the association between HCV and CHD among HIV-infected individuals are sparse, the results are inconsistent, and none of these studies used competing risk models. 3, 4 However, our results (Table 3; model 2, with death as a censored event) are very consistent with another study of 19 424 HIV infected Veterans, which reported a significant association between HCV infection and cardiovascular diseases (HR, 1.20; 95% CI, 1.04 to 1.38) after adjusting for hypertension, age, type 2 diabetes, and smoking. 5 We used competing risk models in the present study because HIVϩ HCVϩ Veterans had higher adjusted incident mortality rates. We conducted these analyses to ensure that mortality was not obscuring the association between HIV, HCV, and incident CHD. Whether the referent group was HIVϪHCVϪ or HIVϩHCVϪ Veterans, HIVϩHCVϩ Veterans had a significantly increased risk of CHD. This asso-ciation persisted regardless of whether a Cox or competing risk model was used. Of note, whether the competing risk model increased (Table 2 ) or modestly decreased ( Table 3) the estimation of CHD risk among HIVϩHCVϩ Veterans was largely determined by the mortality rates of and the propensity estimates for CHD death or development of CHD in the follow-up period among those who died of a non-CHD death among the referent groups. In our analyses among HIV-infected Veterans, ART was associated with an increased risk of CHD and a reduced risk of death. Thus, ART almost certainly influenced the association between HIV, HCV, and the risk of CHD.
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This analysis was not designed to determine whether HCV monoinfection is associated with increased risk of CHD. Among HIV-uninfected individuals, several studies report that HCV infection is associated with a higher prevalence of CHD risk factors, 21, 22 carotid atherosclerosis, [23] [24] [25] and CHD. 26, 27 Other studies report no association. 28 -30 Our results did not demonstrate a significant association between HIVϪHCVϩ infection and incident CHD. However, the 1 p = 0.003 
confidence intervals around these estimates were wide and did not preclude a clinically important difference in risk (up to 70% to 80% increased HR compared with HIVϪHCVϪ). The width of these confidence intervals may be attributable to the small number of CHD events among the HIVϪHCVϩ Veterans in this study.
The mechanism by which the HIV virus influences CHD risk remains unknown. One hypothesis suggests that chronic HIV infection causes microbial translocation of intestinal bacterial products leading to increased immune activation. 31 Interestingly, markers of microbial translocation are also associated with the progression of HCV and cirrhosis, each of which may also stimulate an increased immune response. 32 Whether HIV and HCV viruses increase the risk of CHD risk through microbial translocation and increased immune response is not known.
The present study has limitations. First, because our population consists entirely of men, our results may not be generalizable to women. The use of ICD-9 codes for CHD diagnoses may have resulted in some misclassification; however, prior work suggests these codes have high positive predictive values and demonstrate good agreement with formal chart review adjudication processes. Moreover, the ICD-9 codes used in this analysis represent both inpatient and outpatient records. This is important because CHD events occurring outside the VA system could not be captured if only VA inpatient hospitalization data were used to identify CHD events. Third, cause of death data were not available; however, our competing risk models were specifically designed to identify among those who died, who were at greatest risk of CHD death and to incorporate that risk in our analyses. Fourth, without HCV viral RNA values, we could not account for those individuals who might have spontaneously cleared their HCV infection or had false-positive tests. Fifth, we did not incorporate treatment for HCV infection; however, our prior studies in clinical settings show that treatment rates are low for HCV monoinfected people and even lower for HIV-HCV-coinfected patients. 33 In conclusion, HIVϩHCVϩ Veterans have an increased risk of incident CHD after adjustment for traditional CHD risk factors, and HIV factors including antiretroviral therapy, CD4 count, and HIV-1 RNA-1 RNA compared with HIVϩHCVϪ and HIVϪHCVϪ Veterans. Further investigations should focus on the mechanism of HCV infection and the risk of CHD among HIV-infected individuals.
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